Live feed08:00:00·13mPRReleasevia QuantisnowTyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026ByQuantisnow·Wall Street's wire, on your screen.TYRA· Tyra Biosciences Inc.Health Care
